The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration
Abstract
The development of therapeutics for effective treatments of retinal diseases is significantly constrained by various biological barriers. We herein report a nanomedicine strategy to develop nanotherapeutics featured with not only high retinal permeability but also sustained bioactive delivery. Specifically, the nanotherapeutics are rationally designed via aminolysis of resveratrol-encapsulated polycaprolactone nanoparticles (R@PCL NPs), followed by the formation of amide linkages with carboxyl-terminated transacting activator of transcription cell penetrating peptide (T) and metformin (M). The R@PCL-T/M NP nanotherapeutics are demonstrated in vitro to possess persistent drug release profiles, good ocular biocompatibility, and potent bioactive activities for targeting prevailing risk factors associated with retinal diseases. In vivo studies indicate that single-dose intravitreal administration of the R@PCL-T/M NPs can effectively improve retinal permeability (∼15-fold increase), prevent loss of endogenous antioxidants, and suppress the growth of abnormal vessels in the retina with macular degeneration for 56 days. This high treatment efficacy can be ascribed to the enhanced retinal permeability of the nanotherapeutics in conjunction with the sustained pharmacological activity of the dual drugs (R and M) in the retinal pigment epithelial region. These findings show a great promise for the development of pharmacological nanoformulations capable of targeting the retina and thereby treating complex posterior segment diseases with improved efficacies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Understanding MAPK Signaling Pathways in Apoptosis
Yue, J., & López, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072346 · Cited by 1,245
FTIR study of polycaprolactone chain organization at interfaces
Elzein, T., Nasser-Eddine, M., Delaite, C., Bistac, S., & Dumas, P. (2004) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2004.02.001 · Cited by 814
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Brown, E. E., DeWeerd, A. J., Ildefonso, C. J., Lewin, A. S., & Ash, J. D. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101201 · Cited by 259
ESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.753 · Cited by 120
Protective Effects of Resveratrol against UVA-Induced Damage in ARPE19 Cells
Chan, C.-M., Huang, C.-H., Li, H.-J., Hsiao, C.-Y., Su, C.-C., Lee, P.-L., & Hung, C.-F. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035789 · Cited by 77
Nanoparticulate drug delivery to the retina
Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00224 · Cited by 59
Cited by
Kailasam, V., Kumara, B. N., Prasad, K. S., & Nirmal, J. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114208 · Cited by 19
Metadata
- Authors
- Nguyen, D. D., Luo, L.-J., Yang, C.-J., & Lai, J.-Y.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-12-16
- Volume
- 17
- Issue
- 1
- Pages
- 168-183
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W4311663425
- Cited by
- 213
- References
- 9
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.